Vertex overdone selloff creates upside opportunity
Concerns surrounding cystic fibrosis drug competition for Vertex are overblown, setting the stock up for a second-half rebound.
Keep reading this one
You've read the thesis and who argued it. A free account opens the argument, what validates it, the risks the show raised, and the moment in the episode where it was said — 3 ideas in full a day, no card.